- Quest Diagnostics (DGX, Financial) to introduce the first commercial diagnostic test for the Oropouche virus by July 2025.
- The test employs cutting-edge PCR technology for early detection, with serology tests scheduled later.
- Backed by CDC contracts, Quest aims to bolster U.S. readiness for emerging public health threats.
Quest Diagnostics (DGX), a leader in diagnostic information services, has announced the launch of a new diagnostic laboratory test for the Oropouche virus, a significant emerging infectious disease in South and Central America and the Caribbean. The test will be available with a prescription by the end of July 2025. This initiative enhances Quest's portfolio in infectious disease diagnostics and aligns with its strategic CDC partnership established in September 2024 to bolster U.S. healthcare preparedness for emerging threats.
The newly developed test at Quest's San Juan Capistrano laboratory uses polymerase chain reaction (PCR) technology to identify the virus RNA during the early stages of infection. Later in the quarter, Quest plans to implement serology testing which will detect antibodies, providing a comprehensive diagnostic solution to cover the full disease spectrum. This dual-method approach ensures both early-stage detection and confirmation of later-stage infections.
While the current risk of Oropouche virus in North America remains low, its spread in the Americas has prompted Quest to prepare U.S. healthcare systems for a potential outbreak. The disease, transmitted by biting midges and some mosquito species, can lead to severe neurological conditions like meningitis and encephalitis, making timely detection crucial.
This endeavor follows Quest's earlier development of the Avian Influenza A H5 test under its CDC contracts, showcasing their capacity to rapidly develop diagnostic solutions. The funding acquired through these contracts allows Quest to maintain readiness for quick mobilization in response to public health needs, demonstrating the company's commitment to public health safety and innovation in infectious disease diagnostics.
Quest Diagnostics continues to play a vital role in ensuring the U.S. is prepared for public health emergencies by providing scalable testing facilities, which can complement public health labs if required. This launch is pivotal in positioning Quest as a proactive leader in diagnostic services, ready to address emerging infectious threats globally.
